An evidence-based approach in the treatment of Huntington's disease

Parkinsonism and Related Disorders

Volumn 18, Issue 4, 2012, Pages 316-320

  Mestre, T A ^a   Ferreira, J J ^a  

^a INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

Author keywords

Anxiety; Apathy; Chorea; Cognition; Depression; Huntington's disease; Irritability; Treatment

Indexed keywords

ALPHA TOCOPHEROL; AMANTADINE; BACLOFEN; BOTULINUM TOXIN; CITALOPRAM; CLONAZEPAM; CLONIDINE; DIMEBON; DONEPEZIL; DOPAMINE RECEPTOR STIMULATING AGENT; FLUOXETINE; IDEBENONE; LAMOTRIGINE; LEVODOPA; MEMANTINE; METHYLPHENIDATE; MODAFINIL; NABILONE; NEUROLEPTIC AGENT; PERINDOPRIL; PIMOZIDE; PROPRANOLOL; RILUZOLE; SEROTONIN UPTAKE INHIBITOR; SULPIRIDE; TETRABENAZINE; TIAPRIDE; UBIDECARENONE; UNINDEXED DRUG; VALPROIC ACID;

AKATHISIA; ANXIETY DISORDER; APATHY; CHOREA; COGNITIVE DEFECT; DEPRESSION; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TREATMENT FAILURE; DYSTONIA; EVIDENCE BASED MEDICINE; GAIT DISORDER; HUMAN; HUNTINGTON CHOREA; INSOMNIA; IRRITABILITY; MYOCLONUS; OBSESSIVE COMPULSIVE DISORDER; PARKINSONISM; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SLEEP DISORDER; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; TIC; TREATMENT DURATION; TREATMENT RESPONSE;

ANTIPSYCHOTIC AGENTS; BEHAVIORAL SYMPTOMS; BIOMEDICAL RESEARCH; COGNITION DISORDERS; EVIDENCE-BASED MEDICINE; HUMANS; HUNTINGTON DISEASE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84860385532     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2011.10.021     Document Type: Review

References (59)

1. European Medicines Agency E. Orphan designation. 2011 [cited 2011 4th February]; Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000029.jsp&murl=menus/regulations/regulations.jsp&mid=WC0b01ac05800240ce&jsenabled=true.
2. Clinicaltrials.gov. 2010; Available from: http://clinicaltrials.gov/ct2/results?term=Huntington%27s+disease&cond=%22Huntington+Disease%22.
3. Mestre T., Ferreira J., Coelho M.M., Rosa M., Sampaio C. Therapeutic interventions for symptomatic treatment in Huntington's disease. Cochrane Database Syst Rev 2009, CD006456.
4. Mestre T., Ferreira J., Coelho M.M., Rosa M., Sampaio C. Therapeutic interventions for disease progression in Huntington's disease. Cochrane Database Syst Rev 2009, CD006455.
5. European Medicines Agency E Public summary of opinion on orphan designation: Lithium citrate tetrahydrate (in reverse-micelle formulation) for the treatment of Huntington's disease 2011, [cited 2011 4th February]; Available from:. http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2010/02/WC500074740.pdf.
6. Frank S. Tetrabenazine: the first approved drug for the treatment of chorea in US patients with Huntington disease. Neuropsychiatr Dis Treat 2010, 6:657-665.
7. Thibaut F., Faucheux B.A., Marquez J., Villares J., Menard J.F., Agid Y., et al. Regional distribution of monoamine vesicular uptake sites in the mesencephalon of control subjects and patients with Parkinson's disease: a postmortem study using tritiated tetrabenazine. Brain Res 1995, 692:233-243.
8. Pettibone D.J., Totaro J.A., Pflueger A.B. Tetrabenazine-induced depletion of brain monoamines: characterization and interaction with selected antidepressants. Eur J Pharmacol 1984, 102:425-430.
9. HSG Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 2006, 66:366-372.
10. Frank S. Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators. BMC Neurol 2009, 9:62.
11. Quinn N., Marsden C.D. A double blind trial of sulpiride in Huntington's disease and tardive dyskinesia. J Neurol Neurosurg Psychiatry 1984, 47:844-847.
12. Deroover J., Baro F., Bourguignon R.P., Smets P. Tiapride versus placebo: a double-blind comparative study in the management of Huntington's chorea. Curr Med Res Opin 1984, 9:329-338.
13. Roos R.A., Buruma O.J., Bruyn G.W., Kemp B., van der Velde E.A. Tiapride in the treatment of Huntington's chorea. Acta Neurol Scand 1982, 65:45-50.
14. van Vugt J.P., Siesling S., Vergeer M., van der Velde E.A., Roos R.A. Clozapine versus placebo in Huntington's disease: a double blind randomised\ comparative study. J Neurol Neurosurg Psychiatry 1997, 63:35-39.
15. Verhagen Metman L., Morris M.J., Farmer C., Gillespie M., Mosby K., Wuu J., et al. Huntington's disease: a randomized, controlled trial using the NMDA-antagonist amantadine. Neurology 2002, 59:694-699.
16. O'Suilleabhain P., Dewey R.B. A randomized trial of amantadine in Huntington disease. Arch Neurol 2003, 60:996-998.
17. Group HS Dosage effects of riluzole in Huntington's disease: a multicenter placebo-controlled study. Neurology 2003, 61:1551-1556.
18. Landwehrmeyer G.B., Dubois B., de Yebenes J.G., Kremer B., Gaus W., Kraus P.H., et al. Riluzole in Huntington's disease: a 3-year, randomized controlled study. Ann Neurol 2007, 62:262-272.
19. Consroe P., Laguna J., Allender J., Snider S., Stern L., Sandyk R., et al. Controlled clinical trial of cannabidiol in Huntington's disease. Pharmacol Biochem Behav 1991, 40:701-708.
20. Curtis A., Mitchell I., Patel S., Ives N., Rickards H. A pilot study using nabilone for symptomatic treatment in Huntington's disease. Mov Disord 2009, 24:2254-2259.
21. Como P.G., Rubin A.J., O'Brien C.F., Lawler K., Hickey C., Rubin A.E., et al. A controlled trial of fluoxetine in nondepressed patients with Huntington's disease. Mov Disord 1997, 12:397-401.
22. ® study in Huntington's disease Neurosearch 2010, [updated 03 February 2010]; Available from:. http://www.neurosearch.com/Default.aspx%3FID%3D16%26M%3DNews%26PID%3D12%26NewsID%3D15886.
23. ® shows significant effect on total motor function in patients with Huntington's disease although it did not meet the primary endpoint after 12 weeks of treatment. Neurosearch 2010, [14 October 2010]; Available from:. http://www.neurosearch.com/Default.aspx%3FID%3D16%26M%3DNews%26PID%3D12%26NewsID%3D15975.
24. Waters S., Tedroff J., Kieburtz K. Poster 19: Validation of the modified motor score (mMS): a Subscale of the Unified Huntington's disease rating scale (UHDRS) motor score. Neurotherapeutics journal Am Soc for Exp NeuroTherapeutics 2010, 7:144.
25. ® in Huntington's disease. Neurosearch 2010, [28 April 2010]; Available from:. http://www.neurosearch.com/Default.aspx%3FID%3D16%26M%3DNews%26PID%3D12%26NewsID%3D15919.
26. Dahlen P. NeuroSearch announces the results of a meta-analysis of data from a clinical Phase II/III programme with Huntexil® for Huntington's disease. Neurosearch; [4 February 2011]; Available from: http://www.euro-hd.net/html/projects/acr16/NeuroSearch-announcement-30.12.10.pdf.
27. Bonelli R.M., Wenning G.K. Pharmacological management of Huntington's disease: an evidence-based review. Curr Pharm Des 2006, 12:2701-2720.
28. Craufurd D., Thompson J.C., Snowden J.S. Behavioral changes in huntington disease. Neuropsychiatry Neuropsychol Behav Neurol 2001, 14:219-226.
29. Duff K., Paulsen J.S., Beglinger L.J., Langbehn D.R., Stout J.C. Psychiatric symptoms in Huntington's disease before diagnosis: the predict-HD study. Biol Psychiatry 2007, 62:1341-1346.
30. Marshall J., White K., Weaver M., Flury Wetherill L., Hui S., Stout J.C., et al. Specific psychiatric manifestations among preclinical Huntington disease mutation carriers. Arch Neurol 2007, 64:116-121.
31. van Duijn E., Kingma E.M., van der Mast R.C. Psychopathology in verified Huntington's disease gene carriers. J Neuropsychiatry Clin Neurosci 2007, 19:441-448.
32. Starkstein S.E., Leentjens A.F. The nosological position of apathy in clinical practice. J Neurol Neurosurg Psychiatry 2008, 79:1088-1092.
33. Blackwell A.D., Paterson N.S., Barker R.A., Robbins T.W., Sahakian B.J. The effects of modafinil on mood and cognition in Huntington's disease. Psychopharmacology (Berl) 2008, 199:29-36.
34. EURO-HD. 2011 [cited 2011 Jan 2011]; Available from: http://www.euro-hd.net/html/disease/archive/ehdn-newsletter-jan2011.pdf.
35. Di Maio L., Squitieri F., Napolitano G., Campanella G., Trofatter J.A., Conneally P.M. Onset symptoms in 510 patients with Huntington's disease. J Med Genet 1993, 30:289-292.
36. Kremer B., Clark C.M., Almqvist E.W., Raymond L.A., Graf P., Jacova C., et al. Influence of lamotrigine on progression of early Huntington disease: a randomized clinical trial. Neurology 1999, 53:1000-1011.
37. Depression: the treatment and management of depression in adults 2009, National Institute for Health and Clinical Excellence.
38. van Duijn E. Treatment of irritability in Huntington's disease. Curr Treat Options Neurol 2010, 12:424-433.
39. Cubo E., Shannon K.M., Tracy D., Jaglin J.A., Bernard B.A., Wuu J., et al. Effect of donepezil on motor and cognitive function in Huntington disease. Neurology 2006, 67:1268-1271.
40. Beglinger L.J., Adams W.H., Paulson H., Fiedorowicz J.G., Langbehn D.R., Duff K., et al. Randomized controlled trial of atomoxetine for cognitive dysfunction in early Huntington disease. J Clin Psychopharmacol 2009, 29:484-487.
41. Goety C.G., Tanner C.M., Cohen J.A., Thelen J.A., Carroll V.S., Klawans H.L., et al. L-acetyl-carnitine in Huntington's disease: double-blind placebo controlled crossover study of drug effects on movement disorder and dementia. Mov Disord 1990, 5:263-265.
42. Puri B.K., Bydder G.M., Counsell S.J., Corridan B.J., Richardson A.J., Hajnal J.V., et al. MRI and neuropsychological improvement in Huntington disease following ethyl-EPA treatment. Neuroreport 2002, 13:123-126.
43. Puri B.K., Leavitt B.R., Hayden M.R., Ross C.A., Rosenblatt A., Greenamyre J.T., et al. Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial. Neurology 2005, 65:286-292.
44. HSG Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: the TREND-HD study. Arch Neurol 2008, 65:1582-1589.
45. HSG A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology 2001, 57:397-404.
46. Ranen N.G., Peyser C.E., Coyle J.T., Bylsma F.W., Sherr M., Day L., et al. A controlled trial of idebenone in Huntington's disease. Mov Disord 1996, 11:549-554.
47. Murman D.L., Giordani B., Mellow A.M., Johanns J.R., Little R.J., Hariharan M., et al. Cognitive, behavioral, and motor effects of the NMDA antagonist ketamine in Huntington's disease. Neurology 1997, 49:153-161.
48. Kieburtz K., Feigin A., McDermott M., Como P., Abwender D., Zimmerman C., et al. A controlled trial of remacemide hydrochloride in Huntington's disease. Mov Disord 1996, 11:273-277.
49. Corey-Bloom J.A. Pilot study of memantine for cognitive and behavioral dysfunction in Huntington's disease 2010, [29 Novembre 2010]; Available from:. http://clinicaltrials.gov/ct2/show/NCT00652457.
50. Randomized A. Placebo-Controlled pilot study in Huntington's disease (CIT-HD) 2010, [29 Novembre 2010]; Available from:. http://clinicaltrials.gov/ct2/show/record/NCT00271596.
51. Kieburtz K., McDermott M.P., Voss T.S., Corey-Bloom J., Deuel L.M., Dorsey E.R., et al. A randomized, placebo-controlled trial of latrepirdine in Huntington disease. Arch Neurol 2010, 67:154-160.
52. Medivation I. Pfizer and Medivation Announce results from phase 3 Horizon trial of Dimebon in huntington disease 2011, [cited 2011 April 2011].
53. Peyser C.E., Folstein M., Chase G.A., Starkstein S., Brandt J., Cockrell J.R., et al. Trial of d-alpha-tocopherol in Huntington's disease. Am J Psychiatry 1995, 152:1771-1775.
54. Shoulson I., Odoroff C., Oakes D., Behr J., Goldblatt D., Caine E., et al. A controlled clinical trial of baclofen as protective therapy in early Huntington's disease. Ann Neurol 1989, 25:252-259.
55. Hersch S.M., Gevorkian S., Marder K., Moskowitz C., Feigin A., Cox M., et al. Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. Neurology 2006, 66:250-252.
56. A futility study of minocycline in Huntington's disease. Mov Disord 2010, 25:2219-2224.
57. Tabrizi S.J., Scahill R.I., Durr A., Roos R.A., Leavitt B.R., Jones R., et al. Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol 2011, 10:31-42.
58. Drijgers R.L., Aalten P., Winogrodzka A., Verhey F.R., Leentjens A.F. Pharmacological treatment of apathy in neurodegenerative diseases: a systematic review. Dement Geriatr Cogn Disord 2009, 28(1):13-22.
59. Generalised anxiety disorder and panic disorder (with or without agoraphobia) in adults. National Institute for Health and Clinical Excellence; 2011.